---
title: "Novo Nordisk ADR resumes trading, instantly plummeting, with a decline expanding to 8.4%"
description: "Novo Nordisk ADR resumed trading, instantly plummeting, with a decline expanding to 8.4%. Risk warning and disclaimer: The market has risks, and investment requires caution. This article does not cons"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274689185.md"
published_at: "2026-02-03T16:57:59.000Z"
---

# Novo Nordisk ADR resumes trading, instantly plummeting, with a decline expanding to 8.4%

> Novo Nordisk ADR resumed trading, instantly plummeting, with a decline expanding to 8.4%. Risk warning and disclaimer: The market has risks, and investment requires caution. This article does not constitute personal investment advice and does not take into account the specific investment goals, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article align with their specific circumstances. Investing based on this is at your own risk

Novo Nordisk ADR resumed trading, instantly plummeting, with the decline expanding to 8.4%.

Risk Warning and Disclaimer

The market has risks, and investment requires caution. This article does not constitute personal investment advice and does not take into account the specific investment objectives, financial conditions, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article align with their specific circumstances. Investment based on this is at one's own risk.

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 期权热点｜周一 NVO 大跌 16%，部分看跌期权飙升 6775% | 美东时间 02 月 23 日，诺和诺德公司期权总成交 316590 张，看涨期权占比 57%，看跌期权占比 42%。 | [Link](https://longbridge.com/en/news/276681569.md) |
| 在股价回调以及 GLP-1 增长前景的背景下，评估诺和诺德公司（NYSE:NVO）的估值 | 诺和诺德公司 (NYSE:NVO) 在过去一个月的股价下跌了 24%，过去一年总回报下降了 45%。该公司报告的年收入为 309,064.0 百万丹麦克朗，净收入为 102,434.0 百万丹麦克朗，均增长约 4%。目前股价为 47.42  | [Link](https://longbridge.com/en/news/276640505.md) |
| 美股夜盘异动：Talphera 高管集体增持，夜盘股价涨 10.74%！市场信心回暖还是风险加剧？ | Talphera 夜盘涨 10.74%；诺和诺德公司夜盘涨 0.45%，成交额达到 2.37 百万美元；礼来夜盘跌 0.24%，成交额达到 98.78 万美元；辉瑞成交额达到 17.78 万美元。 | [Link](https://longbridge.com/en/news/276681743.md) |
| 诺和诺德公司提议任命两名新的董事会成员 | 丹麦制药公司诺和诺德公司提议在 3 月 26 日于哥本哈根举行的年度股东大会上新增三名董事会成员。提议的成员包括海伦娜·萨克森、扬·范·德·温克尔和拉莫娜·塞奎拉。萨克森此前已宣布辞去 Sobi 的职务以加入诺和诺德。还提议重新选举董事长拉 | [Link](https://longbridge.com/en/news/276442777.md) |
| 关键事实：诺和诺德公司在 CagriSema 上面临挑战；计划进行 350 亿美元的并购 | 摩根大通的分析师对 CagriSema 的表现不佳表示担忧，这可能会影响诺和诺德在竞争激烈的肥胖治疗领域的需求和长期销售。诺和诺德预计今年将拨出多达 350 亿美元用于潜在的并购，原因是 CagriSema 的试验结果令人失望。诺和诺德承认 | [Link](https://longbridge.com/en/news/276670594.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.